Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Unknown 5Completed 5Recruiting 4Terminated 2Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 58Ovarian Neoplasms 7Neoplasm Metastasis 7Endometrial Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Neoplasms 4Hereditary Sensory and Autonomic Neuropathies 4Advanced Breast Cancer 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Colorectal Neoplasms 3Neoplasms by Site 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Diseases 2Advanced Solid Tumors 2Advanced Solid Tumor 2Unilateral Breast Neoplasms 1Spinocerebellar Degenerations 1Salivary Gland Neoplasms 1Recurrence 1Prostatic Neoplasms 1Melanoma 1Lung Neoplasms 1Locoregional Recurrence 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1HR+/HER2- Breast Cancer 1HR+ Breast Cancer 1

Interventions

Fulvestrant 4trastuzumab deruxtecan 2elacestrant 2Vinorelbine 2AZD9833 2toripalimab 1talazoparib 1ribociclib 1pyrotinib 1palbociclib 1olaparib 1exemestane 1eribulin 1disitamab vedotin 1dalpiciclib 1apatinib 1abemaciclib 1Selective Estrogen Receptor Modulators 1Radiotherapy 1RAD1901 1Letrozole 1Injections 1Gonadotropin-Releasing Hormone 1Everolimus 1Capecitabine 1Aromatase Inhibitors 1Anastrozole 1AZD5305 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Advanced Breast Cancer × Fulvestrant × Clear all
NCT06380751 2026-05-15

EvoPAR-BR01

AstraZeneca

Phase 3 Recruiting
500 enrolled
Breast

Advanced Breast Cancer

NCT07180160 2025-11-18

ITHRAN

RenJi Hospital

Phase 2 Recruiting
123 enrolled
Breast

Advanced Breast Cancer

NCT05536128 2025-04-17

Post-CDK

Seoul National University Hospital

Phase 2 Recruiting
64 enrolled
Breast

Advanced Breast Cancer

NCT06447623 2024-06-07

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Fudan University

Phase 3 Recruiting
184 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡